News

Aged Care Insite20m

New Alzheimer’s drug rejected by PBS, patients to pay up to $80k a year

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small C…

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company committed to developing, ...
TipRanks on MSN10h

Eli Lilly’s Promising Study on Lebrikizumab for Pediatric Eczema

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company, in collaboration ...

Novo Nordisk: Undervalued Pharma Heavyweight With Upside Potential

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...